Loss of Mfn1 but not Mfn2 enhances adipogenesis

PLoS One. 2024 Dec 31;19(12):e0306243. doi: 10.1371/journal.pone.0306243. eCollection 2024.

Abstract

Objective: A biallelic missense mutation in mitofusin 2 (MFN2) causes multiple symmetric lipomatosis and partial lipodystrophy, implicating disruption of mitochondrial fusion or interaction with other organelles in adipocyte differentiation, growth and/or survival. In this study, we aimed to document the impact of loss of mitofusin 1 (Mfn1) or 2 (Mfn2) on adipogenesis in cultured cells.

Methods: We characterised adipocyte differentiation of wildtype (WT), Mfn1-/- and Mfn2-/- mouse embryonic fibroblasts (MEFs) and 3T3-L1 preadipocytes in which Mfn1 or 2 levels were reduced using siRNA.

Results: Mfn1-/- MEFs displayed striking fragmentation of the mitochondrial network, with surprisingly enhanced propensity to differentiate into adipocytes, as assessed by lipid accumulation, expression of adipocyte markers (Plin1, Fabp4, Glut4, Adipoq), and insulin-stimulated glucose uptake. RNA sequencing revealed a corresponding pro-adipogenic transcriptional profile including Pparg upregulation. Mfn2-/- MEFs also had a disrupted mitochondrial morphology, but in contrast to Mfn1-/- MEFs they showed reduced expression of adipocyte markers. Mfn1 and Mfn2 siRNA mediated knockdown studies in 3T3-L1 adipocytes generally replicated these findings.

Conclusions: Loss of Mfn1 but not Mfn2 in cultured pre-adipocyte models is pro-adipogenic. This suggests distinct, non-redundant roles for the two mitofusin orthologues in adipocyte differentiation.

MeSH terms

  • 3T3-L1 Cells*
  • Adipocytes* / cytology
  • Adipocytes* / metabolism
  • Adipogenesis* / genetics
  • Animals
  • Cell Differentiation
  • Fatty Acid-Binding Proteins / genetics
  • Fatty Acid-Binding Proteins / metabolism
  • Fibroblasts* / metabolism
  • GTP Phosphohydrolases* / genetics
  • GTP Phosphohydrolases* / metabolism
  • Mice
  • Mice, Knockout
  • Mitochondria* / metabolism
  • PPAR gamma / genetics
  • PPAR gamma / metabolism

Substances

  • GTP Phosphohydrolases
  • Mfn2 protein, mouse
  • Mfn1 protein, mouse
  • PPAR gamma
  • Fatty Acid-Binding Proteins

Grants and funding

J.P.M. is supported by a Wellcome Trust fellowship (WT 216329). R.K.S, D.B.S. and S.O'R. are supported by the Wellcome Trust (WT 210752, WT 219417 and WT 214274 respectively), the MRC Metabolic Disease Unit, the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the NIHR Rare Disease Translational Research Collaboration (https://www.mrl.ims.cam.ac.uk/mrc-metabolic-diseases-unit/) MRC_MC_UU_12012.1. J.P. is supported by the Medical Research Council (MRC) (MRC grants MC_UU_00015/7 and MC_UU_00028/5) and a Biotechnology and Biological Sciences Research Council (BBSRC) research grant (BB/W008467/1). L.C.T. is supported by a BBSRC research grant (BB/W008467/1). J.E.N.M. is supported by a MRC New Investigator Grant (MR/S025685/1) and D.J.F. is supported by a Medical Research Council Career Development Award (MR/S007091/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding to the Genomics and Transcriptomics Core is from the MRC Metabolic Diseases Unit [MC_UU_00014/5] and the Wellcome Trust Major Award [208363/Z/17/Z]. The funders had no role in study design, data collection and interpretation, or submitting the work for publication.